Gadoxetic acid
Eovist (gadoxetic acid) is a small molecule pharmaceutical. Gadoxetic acid was first approved as Eovist on 2008-07-03.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Eovist
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| eovist | New Drug Application | 2025-03-05 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
68 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 3 | 2 | — | 3 | 23 | 31 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 3 | 1 | — | 2 | 19 | 25 |
| Carcinoma | D002277 | — | C80.0 | 3 | 1 | — | 2 | 10 | 16 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | 4 | 6 | 10 |
| Fibrosis | D005355 | — | — | — | — | — | 3 | 4 | 7 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | 2 | 4 | 7 |
| Neoplasms | D009369 | — | C80 | — | — | — | 1 | 3 | 4 |
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | 2 | 1 | 4 |
| Disease | D004194 | EFO_0000408 | R69 | — | — | — | 1 | 1 | 2 |
| Cognition | D003071 | EFO_0003925 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Magnetic resonance imaging | D008279 | — | — | 1 | 1 | 1 | — | 3 | 5 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | — | 1 | — | — | 1 | 2 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 1 | — | — | — | 2 |
| Sclerosing cholangitis | D015209 | EFO_0004268 | K83.01 | — | 1 | — | — | 1 | 2 |
| Cholangitis | D002761 | HP_0030151 | K83.0 | — | 1 | — | — | 1 | 2 |
| Pharmacokinetics | D010599 | — | — | 1 | 1 | — | — | — | 1 |
| Drug carriers | D004337 | — | — | 1 | 1 | — | — | — | 1 |
| Biliary tract diseases | D001660 | EFO_0009534 | K83.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Cholangiocarcinoma | D018281 | — | C22.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | — | 5 | 5 |
| Liver failure | D017093 | — | K72.9 | — | — | — | — | 3 | 3 |
| Hepatic insufficiency | D048550 | — | — | — | — | — | — | 2 | 2 |
| Hepatitis | D006505 | — | K75.9 | — | — | — | — | 1 | 1 |
| Chronic hepatitis | D006521 | — | K73.9 | — | — | — | — | 1 | 1 |
| Intrahepatic cholestasis | D002780 | — | — | — | — | — | — | 1 | 1 |
| Bile duct diseases | D001649 | — | — | — | — | — | — | 1 | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Diagnosis | D003933 | — | — | — | — | — | — | 1 | 1 |
| Hypertrophy | D006984 | EFO_0002460 | — | — | — | — | — | 1 | 1 |
Show 18 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Gadoxetic acid |
| INN | gadoxetic acid |
| Description | Gadoxetic acid is a gadolinium-based MRI contrast agent. Its salt, gadoxetate disodium, is marketed as Primovist in Europe and Eovist in the United States by Bayer HealthCare Pharmaceuticals.
|
| Classification | Small molecule |
| Drug class | gadolinium derivatives (principally for diagnostic use) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2221312 |
| ChEBI ID | — |
| PubChem CID | 131704314 |
| DrugBank | DB08884 |
| UNII ID | 3QJA87N40S (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,373 documents
View more details
Safety
Black-box Warning
Black-box warning for: Eovist
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
18 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use